Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens

By K. Ng, J. A. Ferreyra, S. Higginbottom, J. Lynch, P. Kashyap, Smita Gopinath, Natasha Naidu, B. Choudhury, B. Weimer, D. Monack and 1 more. Nature, 2013

959 citations recorded by the source corpus.

The human intestine, colonized by a dense community of resident microbes, is a frequent target of bacterial pathogens. Undisturbed, this intestinal microbiota provides protection from bacterial infections. Conversely, disruption of the microbiota with oral antibiotics often precedes the emergence of several enteric pathogens. How pathogens capitalize upon the failure of microbiota-afforded protection is largely unknown. Here we show that two antibiotic-associated pathogens, Salmonella enterica serovar Typhimurium (S. typhimurium) and Clostridium difficile, use a common strategy of catabolizing microbiota-liberated mucosal carbohydrates during their expansion within the gut. S. typhimurium accesses fucose and sialic acid within the lumen of the gut in a microbiota-dependent manner, and genetic ablation of the respective catabolic pathways reduces its competitiveness in vivo. Similarly, C. difficile expansion is aided by microbiota-induced elevation of sialic acid levels in vivo. Colonization of gnotobiotic mice with a sialidase-deficient mutant of Bacteroides thetaiotaomicron, a model gut symbiont, reduces free sialic acid levels resulting in C. difficile downregulating its sialic acid catabolic pathway and exhibiting impaired expansion. These effects are reversed by exogenous dietary administration of free sialic acid. Furthermore, antibiotic treatment of conventional mice induces a spike in free sialic acid and mutants of both Salmonella and C. difficile that are unable to catabolize sialic acid exhibit impaired expansion. These data show that antibiotic-induced disruption of the resident microbiota and subsequent alteration in mucosal carbohydrate availability are exploited by these two distantly related enteric pathogens in a similar manner. This insight suggests new therapeutic approaches for preventing diseases caused by antibiotic-associated pathogens.

Subfields: Food Science, Infectious Diseases, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/43ba90c005453fb43dcf713a54ae5bd9c6e48712

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Food Science

In Infectious Diseases

In Molecular Biology

Citations in the corpus

The Intestinal Microbiome in Early Life: Health and Disease (2014, background): “difficile is a common infection associated with the antibiotic disturbed gut microbiota (109).”
Impact of antibiotics on the human microbiome and consequences for host health (2022, background): “Studies have shown that antibiotic treatment in mice increases the levels of sialic acid and succinate which increase the susceptibility of the host to Salmonella and C. difficile infections (Ferreyra et al., 2014; K. M. Ng et al., 2013).”
Role of the Microbiota in Immunity and inflammation (2014, background): “Alteration of nutrient availability by thehostmicrobiota canalsohaveprofound consequences on the expression of virulence genes and growth rateof pathogenssuchasenterohemorragicE. coliorClostridium difficile (Kamada et al., 2013; Ng et al., 2013; Pacheco et al., 2012).”
The composition of the gut microbiota throughout life, with an emphasis on early life (2015, background): “Furthermore, recent work showed that host-derived fucose signaling, activated through the microbiota, can modulate pathogenic intestinal colonization (94, 95) indicating that mucin glycosylation has a selective capacity on microbial ecology.”
Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease (2017, background): “difficile, used a common strategy of cataboliz ing microbiota-liberated mucosal sugars, such as fucose and sialic acid, during their expansion within the gut (45).”
Mechanisms of inflammation-driven bacterial dysbiosis in the gut (2016, neutral): “Typhimurium and Clostridium difficile.(59,78)”
Intestinal permeability – a new target for disease prevention and therapy (2014, background): “Pathogens, as well as usage of antibiotics, might disturb the intestinal mucus layer, either by enhancing mucus degradation, or by inhibiting the normal commensal triggers for mucus production [86].”
Antibiotics and the gut microbiota. (2014, positive): “As mentioned above, recent work suggests that increased nutrient availability in the absence of certain scavenging commen-sals depleted by antibiotic treatment contributes to pathogenic proliferation (16).”
Core microbiomes for sustainable agroecosystems (2018, background): “Even if shifts from unfavourable (host-damaging) microbiome types occur as consequences of large perturbation (for example, antibiotic or fungicide treatment), such shifts would often result in unexpected fluctuations of microbiome structure 43,44 .”
Mechanisms and consequences of intestinal dysbiosis (2017, background): “Antibiotic treatment has been shown to disturb microbiota and lead to increased liberation of sialic acid, which fuels the expansion of the pathogens Salmonella enterica serovar Typhimurium and Clostridium difficile in a mouse model [84].”
Antibiotic-Induced Changes in the Intestinal Microbiota and Disease. (2016, background): “commensals competing for sugars liberated before treatment, increasing nutrient availability and favoring pathogen expansion through a limited time-window (peaking at day 1 and ending at day 3 after antibiotic treatment for this study) [78].”
Mucin glycan foraging in the human gut microbiome (2015, background): “Recent findings showed that alterations in mucosal carbohydrate availability impact on the composition of microbial species (Martens et al., 2008; Ng et al., 2013; Tong et al., 2014).”